Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
12 mars 2024 08h30 HE
|
Inozyme Pharma Inc.
– Topline data from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in early April – – Phase 1 trial of INZ-701 in end-stage kidney disease (ESKD)...
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference
26 févr. 2024 08h30 HE
|
Inozyme Pharma Inc.
BOSTON, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the...
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 févr. 2024 08h30 HE
|
Inozyme Pharma Inc.
BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the...
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 déc. 2023 08h30 HE
|
Inozyme Pharma Inc.
BOSTON, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the...
Inozyme Pharma to Participate in Upcoming Investor Conferences
09 nov. 2023 08h30 HE
|
Inozyme Pharma Inc.
BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for...
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
07 nov. 2023 08h30 HE
|
Inozyme Pharma Inc.
– Patient recruitment underway in ENERGY-3 Pivotal Trial of INZ-701 in pediatric patients with ENPP1 Deficiency; topline data expected mid-2025 – – Topline data readouts from ongoing Phase 1/2...
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 nov. 2023 16h15 HE
|
Inozyme Pharma Inc.
BOSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY)(“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the...
Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023
26 oct. 2023 08h30 HE
|
Inozyme Pharma Inc.
BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for...
Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions
10 oct. 2023 08h30 HE
|
Inozyme Pharma Inc.
BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for...
Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting
06 oct. 2023 08h30 HE
|
Inozyme Pharma Inc.
BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for...